Analyst Upgrades: Amazon.com, Baxter, and OvaScience

Analysts upwardly revised their ratings and price targets on Amazon.com, Inc. (AMZN), Baxter International Inc (BAX), and OvaScience Inc (OVAS)

May 10, 2016 at 10:09 AM

Analysts are weighing in on e-tail stock Amazon.com, Inc. (NASDAQ:AMZN), healthcare products producer Baxter International Inc (NYSE:BAX), and fertility firm OvaScience Inc (NASDAQ:OVAS). Here's a quick roundup of today's bullish brokerage notes on AMZN, BAX, and OVAS.

AMZN announced the launch of the YouTube-like Amazon Video Direct this morning, and also received a price-target hike at Bernstein to $1,000 from $770 -- all-time-high territory for the shares. Out of the gate, the stock is 2.7% higher at $698.31, bringing its modest year-to-date lead to 3.3% -- but, earlier, it touched a record high of $699.71. Meanwhile, short-term options traders have been more put-skewed than usual toward Amazon.com, Inc. The stock's Schaeffer's put/call open interest ratio (SOIR) of 1.29 ranks in the 83rd percentile of its annual range. Looking ahead, AMZN's annual shareholder meeting is scheduled to take place one week from today.

BAX is down 0.4% at $45 -- though it's just below its May 9 record high of $45.52 -- even after the drugmaker upped its earnings outlook for 2018 through 2020. Likewise, the company said it expects to generate a free cash flow of $1.75 billion by the end of the decade. Leerink, Cowen, and UBS responded by upwardly revising their price targets on Baxter International Inc. Future upgrades are a possibility, as well, considering 10 of 11 analysts rate the stock a "hold" or worse. One potential catalyst for more upbeat attention is today's BofA-Merrill Lynch Health Care Conference, with BAX set to make an appearance this afternoon.

OVAS has soared 4.9% to trade at $7.42, following a price-target hike to $8 from $7 at Ladenburg Thalmann. That said, since its late-April peak of $11.66, the stock has surrendered 36% of its value, and is now testing a potential layer of resistance in the form of its 80-day moving average. Short sellers may be uneasy amid OvaScience Inc's upside move this morning. A lofty 32.4% of the stock's float is sold short, and it would take over four weeks to cover these positions, based on OVAS' average daily trading volume.

Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!

Follow @Schaeffers

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade. Professional traders have rushed into the market and are making a mint. Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.